A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients.
Two hundred twenty-four outpatients with major depression entered a 6-week, five-center, double-blind trial of bupropion 300 mg/day and placebo. A total of 216 patients were included in the efficacy analysis. In the combined center analysis, greater efficacy for bupropion was found on one or more measures (Hamilton Rating Scale for Depression, Montgomery-Asberg Depression Rating Scale, and Clinical Global Impressions) at treatment Days 21, 28, 35, and 42. Bupropion was well tolerated; only four adverse events were reported at least 5% more often in the bupropion group than in the placebo group. Six bupropion patients versus 5 placebo patients discontinued treatment because of adverse events. This study extends earlier findings of efficacy for higher-dose treatment in an inpatient population to lower-dose treatment in an outpatient population.
Lineberry
C G
CG
Burroughs Wellcome Co., Research Triangle Park, N.C. 27709.
Johnston
J A
JA
Raymond
R N
RN
Samara
B
B
Feighner
J P
JP
Harto
N E
NE
Granacher
R P
RP
Weisler
R H
RH
Carman
J S
JS
Boyer
W F
WF
D000328:Adult; D000553:Ambulatory Care; D000928:Antidepressive Agents / Q000008:administration & dosage*; D016642:Bupropion; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D010919:Placebos; D011427:Propiophenones / Q000008:administration & dosage*; D011569:Psychiatric Status Rating Scales; D016032:Randomized Controlled Trials as Topic
D000928:Antidepressive Agents; D010919:Placebos; D011427:Propiophenones; D016642:Bupropion